Log in
Enquire now

Clinical Studies Sponsored by BIOCAD

Clinical Studies Sponsored by BIOCAD
Clinical Studies Sponsored by Alnylam Pharmaceuticals
Clinical Studies Sponsored by University of Connecticut
Clinical Studies Sponsored by Monash University
List of companies in AC Capital's investment portfolio
Alzheimer's disease venture capital investors
Clinical Studies where
Trial Sponsor
is
Name
Description
NCT Number
Health Conditions in Trial
Clinical Trial Start Date
Study Completion Date
Clinical Trial Study Type
‌
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

NCT06333210
‌
Axial spondyloarthritis
December 25, 2023
2028
Interventional
‌
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

NCT06296121
Multiple myeloma
Multiple myeloma
December 21, 2023
2026
Interventional
‌
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children with Moderate to Severe Plaque Psoriasis

NCT06640517
August 8, 2024
2028
Interventional
‌
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

NCT06640530
March 21, 2024
2027
Interventional
‌
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma

NCT06668792
2024
2028
Interventional
‌
The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

NCT03693950
‌
Healthy
March 28, 2017
July 3, 2017
Interventional
‌
Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

NCT05407779
‌
Healthy
January 22, 2021
2023
Interventional
‌
Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04060264
‌
Paroxysmal nocturnal hemoglobinuria
April 4, 2019
December 30, 2020
Interventional
‌
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

NCT02762994
Psoriasis
Psoriasis
2016
2017
Interventional
‌
Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

NCT03519243
Anemia
Anemia
October 24, 2017
December 10, 2018
Interventional
‌
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

NCT01740089
Hepatitis
Hepatitis
Hepatitis C
Hepatitis C
2011
2013
Interventional
‌
Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis

NCT02744196
Rheumatoid arthritis
Rheumatoid arthritis
2015
2017
Interventional
‌
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

NCT01889433
Hepatitis
Hepatitis
Hepatitis C
Hepatitis C
July 10, 2013
December 2, 2015
Interventional
‌
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

NCT01764022
2012
2017
Interventional
‌
DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

NCT04811443
January 12, 2021
June 12, 2022
Observational
‌
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

NCT03912402
Cervical cancer
Cervical cancer
December 25, 2018
July 7, 2020
Interventional
‌
First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects

NCT03103438
‌
Healthy
2016
2017
Interventional
‌
Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT02762838
Rheumatoid arthritis
Rheumatoid arthritis
2016
2018
Interventional
‌
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients

NCT02506868
Anemia
Anemia
Chronic kidney disease
Chronic kidney disease
August 8, 2015
December 21, 2017
Interventional
‌
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

NCT02727907
Multiple sclerosis
Multiple sclerosis
February 12, 2015
August 11, 2017
Interventional
‌
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

NCT03288870
September 19, 2017
August 10, 2021
Interventional
‌
International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis

NCT03447704
Ankylosing spondylitis
Ankylosing spondylitis
February 9, 2018
April 5, 2023
Interventional
‌
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

NCT06112808
May 29, 2023
2027
Interventional
‌
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

NCT02036723
Interventional
‌
Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

NCT02359877
‌
Healthy
2014
2015
Interventional
Results per page:
72 results
0 selected
72 results
0 selected
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us

Explore companies

  • Artificial Intelligence
  • Fintech
  • Biotechnology
  • Cybersecurity
  • Semiconductors
  • Electric Vehicles
  • Cloud Computing
  • Robotics
  • SaaS
  • Renewable Energy
  • Venture Capital
  • Blockchain
  • Browse all →